Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain

Vaccine

Volumn 27, Issue 52, 2009, Pages 7442-7450

  Suter, Mark ^a   Meisinger Henschel, Christine ^b   Tzatzaris, Maria ^b   Hülsemann, Vanessa ^b   Lukassen, Susanne ^b   Wulff, Niels Holger ^b   Hausmann, Jürgen ^b   Howley, Paul ^b   Chaplin, Paul ^b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b Bavarian Nordic GmbH   (Germany)

Author keywords

Biological heterogeneity; MVA; Sequence identity

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE MUTATION; HUMAN; HUMAN CELL; MODIFIED VACCINIA VIRUS ANKARA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; CHICK EMBRYO; DNA, VIRAL; FEMALE; GENOME, VIRAL; HELA CELLS; HUMANS; MICE; MICE, KNOCKOUT; OVARY; PHENOTYPE; SERIAL PASSAGE; VACCINIA VIRUS; VIRUS CULTIVATION; VIRUS REPLICATION;

EID: 70649100173     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.05.095     Document Type: Article

References (27)

1. Stickl H., Hochstein-Mintzel V., and Huber H.C. Primary vaccination against smallpox after preliminary vaccination with the attenuated vaccinia virus strain MVA and the use of a new "vaccination stamp". Munch Med Wochenschr 115 August (35) (1973) 1471-1473
2. Stickl H., Hochstein-Mintzel V., Mayr A., Huber H.C., Schafer H., and Holzner A. MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA). Dtsch Med Wochenschr 99 November (47) (1974) 2386-2392 (author's transl)
3. Mayr A., Hochstein-Mintzel V., and Stickl H. Passage history: Abstammung Eigenschaften und Verwendung des attenuierten Vaccina-Stammes MVA. Infection 3 1 (1975) 6-14
4. Mayr A., and Munz E. Changes in the vaccinia virus through continuing passages in chick embryo fibroblast cultures. Zentralbl Bakteriol [Orig] 195 December (1) (1964) 24-35
5. Altenburger J, inventor; United States Patent 5,185,146.5,185,146. 1993.
6. Mayr A., Stickl H., Muller H.K., Danner K., and Singer H. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism. Zentralbl Bakteriol [B] 167 December (5-6) (1978) 375-390 (author's transl)
7. Meyer H., Sutter G., and Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 72 May (Pt 5) (1991) 1031-1038
8. Moss B., Carroll M.W., Wyatt L.S., Bennink J.R., Hirsch V.M., Goldstein S., et al. Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv Exp Med Biol 397 (1996) 7-13
9. Sutter G., and Staib C. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord 3 September (3) (2003) 263-271
10. Altenburger W., Suter C.P., and Altenburger J. Partial deletion of the human host range gene in the attenuated vaccinia virus MVA. Arch Virol 105 1-2 (1989) 15-27
11. Antoine G., Scheiflinger F., Dorner F., and Falkner F.G. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244 May (2) (1998) 365-396
12. Carroll M.W., and Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 238 November (2) (1997) 198-211
13. Sutter G., and Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA 89 November (22) (1992) 10847-10851
14. Blanchard T.J., Alcami A., Andrea P., and Smith G.L. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol 79 May (Pt 5) (1998) 1159-1167
15. Drexler I., Heller K., Wahren B., Erfle V., and Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol 79 February (Pt 2) (1998) 347-352
16. Wyatt L.S., Carroll M.W., Czerny C.P., Merchlinsky M., Sisler J.R., and Moss B. Marker rescue of the host range restriction defects of modified vaccinia virus Ankara. Virology 251 November (2) (1998) 334-342
17. Chaplin P, Howley P, Meisinger C. United States Patent US 6,913,752 B2. 2005. Ref Type: Generic.
18. Sutter G. Das Genom des Vacciniavirusstammes Ankara und seine Önderung während der Attenuierung. München: Institut für Medizinische Mikrobiologie, Infektions - und Seuchenmedizin der Tierärztlichen Fakultät der Ludwig-Maximillians-Universität; 1989.
19. Grob P., Schijns V.E., van den Broek M.F., Cox S.P., Ackermann M., and Suter M. Role of the individual interferon systems and specific immunity in mice in controlling systemic dissemination of attenuated pseudorabies virus infection. J Virol 73 June (6) (1999) 4748-4754
20. Vollstedt S., Arnold S., Schwerdel C., Franchini M., Alber G., Di Santo J.P., et al. Interplay between alpha/beta and gamma interferons with B, T, and natural killer cells in the defense against herpes simplex virus type 1. J Virol 78 April (8) (2004) 3846-3850
21. Nunez R., Grob P., Baumann S., Zuniga A., Ackermann M., and Suter M. Immortalized cell lines derived from mice lacking both type I and type II IFN receptors unify some functions of immature and mature dendritic cells. Immunol Cell Biol 77 April (2) (1999) 153-163
22. Meisinger-Henschel C., Schmidt M., Lukassen S., Linke B., Krause L., Konietzny S., et al. Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara. J Gen Virol 88 December (Pt 12) (2007) 3249-3259
23. Kaerber G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch Expt Oathol Pharmakol 162 (1931) 480-482
24. Vollstedt S., O'Keeffe M., Odermatt B., Ryf B., Glanzmann B., Riesen M., et al. Treatment of neonatal mice with Flt3 ligand leads to changes in dendritic cell subpopulations associated with enhanced IL-12 and IFN-alpha production. Eur J Immunol 34 July (7) (2004) 1849-1860
25. Esposito J.J., and Fenner F. Poxviruses. Fields Virology. Third Edition (1999)
26. Weltzin R., Liu J., Pugachev K.V., Myers G.A., Coughlin B., Blum P.S., et al. Clonal vaccinia virus grown in cell cultures as a new smallpox vaccine. Nat Med 9 (2003) 1125-1130
27. Spehner D., Drillien R., Proamer F., Houssais-Pêcheur C., Zanta M.A., Geist M., et al. Enveloped virus is the major virus form produced during productive infection with the modified vaccinia virus Ankara strain. Virology 273 July (1) (2000) 9-15